ABL1 and acute myeloid leukemia: In addition to the BCR-ABL/TEL-AML example, diffuse large B-cell lymphoma patients are a candidate for this approach since they can be fractionated into good and poor prognosis groups using DNA microarray data [50-52] or 6 genes [53].